Form 4: REGENXBIO CEO Kenneth T. Mills Executes Option and Sells Shares
SEC Form 4
REGENXBIO's CEO, Kenneth T. Mills, exercised stock options and sold 15,000 shares of common stock on May 14, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On May 14, 2024, Kenneth T. Mills, the President and CEO of REGENXBIO Inc., exercised stock options to acquire 15,000 shares of common stock at a price of $3.76 per share.
- Concurrently, Mills sold 15,000 shares of REGENXBIO common stock at a weighted average price of $15.8148, with prices ranging from $15.59 to $16.25.
- These transactions were executed under a Rule 10b5-1 trading plan.
- Following these transactions, Mills beneficially owns 408,035 shares of REGENXBIO common stock and options to purchase 81,354 shares.
Sentiment
Score: 5
Explanation: This is a neutral event. It's a routine disclosure of insider trading activity under a pre-arranged plan. The CEO is taking profits, which is neither particularly positive nor negative.
Industry Context
This is a routine disclosure of insider trading activity. It is common for executives to exercise stock options and sell shares, often under pre-arranged trading plans to avoid accusations of insider trading.
Key Dates
| Date | Description |
|---|---|
| 05/19/2016 | 25% of the shares subject to the option vested. |
| 05/19/2025 | Expiration date of the previously granted option representing a right to purchase a total of 275,000 shares. |
| 05/14/2024 | Date of the transaction: exercise of stock options and sale of common stock. |
| 05/16/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.